Skip to content
sellWeak10b5-1 plan

Kathleen Goin sold $508k of PVLA

Chief Operating Officer at PALVELLA THERAPEUTICS, INC.. 4,302 shares at an average of $117.99, traded Mar 18, 2026, filed Mar 20, 2026.

Warning score
23
Value
$508k
4,302 shares
Holdings after
0
-100% from before
From 52-week low
+475%
low $19.87, close $114.23
From 52-week high
-23%
high $148.34, as of Mar 18, 2026

Score components

  • Role
    COO
    +20
  • Trade size
    $508k at market
    +18
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +15.6%, 3m +0.5%, 6m +33.8%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

PVLAOct 12, 2026 · close 134.38
Since filing Mar 20, 2026: +19.4%SPY +20.6% · excess -1.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-26-032695, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 18, 2026MOption exercise
Common Stock10b5-1
+2,154$7.14$15k2,154Mar 20, 2026
Mar 18, 2026MOption exercise
Common Stock10b5-1
+2,148$9.08$20k4,302Mar 20, 2026
Mar 18, 2026SOpen-market sale
Common Stock10b5-1
-2,268$117.56$267k2,034Mar 20, 2026
Mar 18, 2026SOpen-market sale
Common Stock10b5-1
-1,730$118.37$205k304Mar 20, 2026
Mar 18, 2026SOpen-market sale
Common Stock10b5-1
-304$119.08$36k0Mar 20, 2026
Mar 18, 2026MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-2,154$0.00$015,089Mar 20, 2026
Mar 18, 2026MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-2,148$0.00$015,036Mar 20, 2026

Related signals

Other insiders at PALVELLA THERAPEUTICS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
40Moderate
PVLAsell 310b5-1
PALVELLA THERAPEUTICS, INC.
Kathleen Goin
Chief Operating Officer
$655k
4,302 shares
-100%
40Moderate
PVLAsell 310b5-1
PALVELLA THERAPEUTICS, INC.
George M Jenkins
director
$4.2M
27,500 shares
-15%
42Moderate
PVLAsell 3
PALVELLA THERAPEUTICS, INC.
Christopher P Kiritsy
director
$49k
313 shares
-56%
33Weak
PVLAsell 210b5-1
PALVELLA THERAPEUTICS, INC.
Kathleen Goin
Chief Operating Officer
$655k
4,302 shares
-100%
25Weak
PVLAsell10b5-1
PALVELLA THERAPEUTICS, INC.
Kathleen Goin
Chief Operating Officer
$642k
4,302 shares
-100%
23Weak
PVLAsell10b5-1
PALVELLA THERAPEUTICS, INC.
Kathleen Goin
Chief Operating Officer
$476k
4,302 shares
-100%
23Weak
PVLAsell10b5-1
PALVELLA THERAPEUTICS, INC.
Kathleen Goin
Chief Operating Officer
$476k
4,302 shares
-100%
24Weak
PVLAsell10b5-1
PALVELLA THERAPEUTICS, INC.
Kathleen Goin
Chief Operating Officer
$547k
4,302 shares
-100%
26Weak
PVLAbuy
PALVELLA THERAPEUTICS, INC.
George M Jenkins
director
$50k
445 shares
+0%
40Moderate
PVLAbuy 2
PALVELLA THERAPEUTICS, INC.
Elaine J Heron
director
$300k
2,400 shares
+5%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Kathleen Goin sold $508k of PVLA | InsiderTell